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Abstract
Background: Anemia is a common disorder in CKD patients. It is largely attributed to decreased erythropoietin
(EPO) production and iron deficiency. Therefore, besides EPO, therapy includes iron replenishment. However, the
latter induces oxidative stress. Haptoglobin (Hp) protein is the main line of defense against the oxidative effects of
Hemoglobin/Iron. There are 3 genotypes: 1–1, 2–1 and 2–2. Hp 2–2 protein is inferior to Hp 1–1 as antioxidant. So
far, there is no evidence whether haptoglobin phenotype affects iron-induced oxidative stress in CKD patients.
Therefore, the present study examines the influence of carnitine treatment on the intravenous iron administration
(IVIR)-induced oxidative stress in CKD patients, and whether Hp phenotype affects this response.
Methods: Trial registration: Current Controlled Trials ISRCTN5700858. This study included 26 anemic (Hb = 10.23 ±
0.28) CKD patients (stages 3–4) that were given a weekly IVIR (Sodium ferric gluconate, [125 mg/100 ml] for
8 weeks, and during weeks 5–8 also received Carnitine (20 mg/kg, IV) prior to IVIR. Weekly blood samples were
drawn before and after each IVIR for Hp phenotype, C-reactive protein (CRP), advanced oxidative protein products
(AOPP), neutrophil gelatinase-associated lipocalin (NGAL), besides complete blood count and biochemical analyses.
Results: Eight percent of CKD patients were Hp1-1, 19 % Hp2-1, and 73 % Hp2-2. IVIR for 4 weeks did not increase
hemoglobin levels, yet worsened the oxidative burden as was evident by elevated plasma levels of AOPP. The
highest increase in AOPP was observed in Hp2-2 patients. Simultaneous administration of Carnitine with IVIR
abolished the IVIR-induced oxidative stress as evident by preventing the elevations in AOPP and NGAL,
preferentially in patients with Hp2-2 phenotype.
Conclusions: This study demonstrates that Hp2-2 is a significant risk factor for IVIR-induced oxidative stress in CKD
patients. Our finding, that co-administration of Carnitine with IVIR preferentially attenuates the adverse
consequences of IVIR, suggests a role for Carnitine therapy in these patients.
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Background
Chronic kidney disease (CKD) is a global public health
problem, affecting tens of millions around the world
[1, 2]. The alarming increase in the prevalence of CKD is
largely attributed to the dramatic global increase of dia-
betes and hypertension incidence [2]. One of the major
complications of CKD, especially the advanced stages of
the disease, is anemia [3]. The latter is associated with
poor clinical outcomes as evident by enhanced inci-
dence of cardiovascular events and the risk of death in
patients with CKD [4–6]. Thus, correction of anemia is
considered as a major component in the integral ther-
apy of CKD adverse consequences [7, 8]. The mecha-
nisms underlying anemia in CKD patients is attributed
to several factors including decreased erythropoietin
(EPO) production, low iron stores, and chronic inflamma-
tion [7]. Therefore, therapy includes not only recombinant
EPO, but also iron replenishment [8–10]. Intravenous
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iron administration (IVIR) in these CKD patients is the
most efficacious and favored route of supplementation to
enhance red blood cell production by recombinant human
erythropoietin administration [7, 8]. There are several iron
preparations for IV administration: iron sucrose, sodium
ferric gluconate, low- and high molecular weight iron
dextran, ferric carboxymaltose, and ferumoxytol [9, 10].
However, despite their efficacy as expressed by im-
proved erythropoietic response in CKD subjects, expos-
ure to IV iron is associated with enhancement of free
radical generation and oxidative stress, thus aggravating
the already existed oxidative burden in these patients
[11–14]. There are several markers of free radical activ-
ities such as carbonyl reactive derivatives (CRD), thiol
groups (SH), malondialdehyde (MDA), and antioxidant
enzyme activities (superoxide dismutase, SOD and
glutathione peroxidase, GPX) [15, 16]. Additional bio-
marker that represents plasma protein oxidation is ad-
vanced protein oxidation products (AOPP), where it
has recently been applied to assess the oxidative stress
and inflammation in several pathological conditions
[17–20]. Enhanced oxidative stress and inflammation
are known to induce direct cellular damage and pos-
sibly increasing the risk of atherosclerotic disease in
CKD and hemodialysis patients [21–23]. Several studies
have shown that the severity of oxidative stress-induced
cardiovascular complications in various disease states is
affected by haptoglobin (Hp) genotype [24, 25]. There
are two classes of functional alleles Hp 1–1, 1–2 and
2–2. Hp binds to free hemoglobin (Hb) released from
blood cells as part of red cell turnover, thus inhibiting
the oxidative tissue damage resulting from free Hb
through heme iron [26, 27]. Hp alleles differ in their
ability to clear free Hb from the plasma where Hp [1]-Hb
complexes are cleared more efficiently from the plasma
than Hp [2]-Hb complexes [27], thus subjects with Hp
2–2 are more prone to oxidative stress [28].
Current criteria for diagnosis and classification of AKI
are highly dependent on changes in SCr [29, 30]. How-
ever, in the setting of acute kidney injury (AKI), the time
relationship between changes in SCr and concomitant
changes in GFR do not allow accurately estimating tim-
ing of injury and severity of dysfunction [31]. Recent
studies have attempted to identify by a genome-wide in-
terrogation strategy genes that are induced very early
after acute ischemia of kidney in animal models, whose
protein products might serve as novel biomarkers for
the initiation phase of AKI. Actually, many potential
markers have been studied, including neutrophil
gelatinase-associated lipocalin (NGAL), kidney injury
molecule- 1 (KIM-1), and others [32, 33]. Among them,
NGAL is one of the most strikingly up-regulated genes
and overexpressed proteins following AKI [32]. NGAL
increased in urine early after renal ischemia in mouse
and rat models [34, 35], yet has not been documented in
human. The additional and earlier finding that the
serum and urine NGAL levels were strikingly elevated in
children with AKI after cardiopulmonary bypass [35]
suggests that NGAL might be a specific, and highly pre-
dictive early biomarker for AKI also in humans. Kidney
injury molecule-1 (KIM-1) is a marker for proximal
tubular injury, the hallmark of virtually all proteinuric,
toxic and ischemic renal diseases [33, 36, 37].
Several interventions have been attempted to counter-
act the deleterious effects of IV induced oxidative stress
in dialysis patients including administration of substances
with antioxidant properties, such as α -tocopherol,
angiotensin converting enzyme inhibitors, vitamin E,
N-acetyl cysteine (NAC) prior to IV iron administra-
tion [15, 38]. Unfortunately, none of these therapeutic
maneuvers exerted beneficial effects against oxygen
free radical injury. However, there is no doubt that any
potential therapies should encounter the altered mito-
chondrial function. One of these approaches is the use
of carnitine since it may preserve mitochondrial func-
tion and subsequently reduced oxidative burden. In
line with this concept, several randomized, controlled
studies and a meta-analysis have shown that L-carnitine
supplementation might have a positive effect on response
to EPO in long term HD patients [19, 39–42]. Unfortu-
nately, there is no evidence whether this approach is also
beneficial in earlier-stage CKD patients. Thus the present
study was designed to investigate the effect of L-Carnitine
therapy on oxidative stress and the inflammatory re-
sponse to intravenous iron administration (IVIR) in CKD
patients. In addition, we examined whether the extent
of oxidative stress in these patients is affected by the
Hp phenotype.
Methods
This was a prospective, non-randomized, open-label,
crossover study of the effects of IV Carnitine supple-
mentation on oxidative stress in CKD patients receiving
IV iron therapy. The study was approved by the Nazareth
Hospital EMMS Human Research Review Committee
and carried at Nazareth Hospital. All patients provided
informed consent. Trial registration: Current Controlled
Trials ISRCTN5700858. (https://clinicaltrials.gov/ct2/show/
NCT02312414), Date of registration is December 5th,
2014.
Inclusion criteria
1. Patients that have been diagnosed as suffering from
chronic kidney diseases at stages 3–4 and confirmed
by MDRD.
2. CKD patients with Hb of ≤ 10.2 g %.
3. At age ≥18 y.
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Exclusion criteria
1. Pregnant women.
2. Patient with CKD stage 5 on Dialysis.
3. Patients with severe liver diseases.
4. Patients with severe CHF.
5. Inter-current illness such as fever.
6. Allergic rhinitis.
Study design
Among 28 eligible patients 2 patients were dropped from
the study due to infection and hospitalization (Fig. 1).
Sample size was determined based on the standard de-
viation of the obtained preliminary data. For this pur-




σ2 k þ 1ð Þ
kΔ2
n2 ¼ kn1
Significance α 5 %
Confidence 1- α 95 %
SD σ 3.0
Strength β 99 %
Effect size delta 0.29
K = 1
Sample size 25
The demographic and laboratory data of the studied
patients are listed in Table 1. This study included 26
anemic (Hb = 10.23 ± 0.25) CKD patients (stages 3–4)
that were given by Dr. ZA at Nazareth Hospital a weekly
IVIR (Sodium ferric gluconate, [125 mg/100 ml] for
8 weeks, and during weeks 5–8 also received Carnitine
(20 mg/kg, IV) prior to IVIR administration). To
minimize potential bias each patient served as its own
control. Weekly blood samples were drawn before and
after each IVIR for C-Reactive protein (CRP), advanced
oxidative protein products (AOPP), neutrophil gelatinase-
associated lipocalin (NGAL), in addition to routine
complete blood count and biochemical analyses.
Chemical and hematological analysis
AOPP (Advanced oxidation protein products)
A novel spectrophotometric assay which allows detecting
advanced oxidation protein products (AOPP) in uremic
plasma was used. AOPP levels were measured with the
Fig. 1 Selection of anemic CKD patients for examination of the effects of carnitine on oxidative stress response to intravenous iron administration
and the impact of haptoglobin phenotype
Table 1 Baseline Demographic and Laboratory Data of the 26
Studied Patients
Parameter Value
Age, mean ± SD (yrs) 63.84 ± 2.84






MDRD-GFR, (ml/min/1.73 m2) 33.2 ± 4.02
Stage of CKD (no.)
Stage 3 11
Stage 4 15
Hemoglobin (g %) 10.3 ± 0.25
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Witko-Sarsat method [19] of optical density analysis in pa-
tient blood samples. AOPP maximum absorption is at a
wavelength of 340 nm under acidic conditions, therefor
this wavelength provides the best indication of the level of
the AOPP in the samples. By size-exclusion chromatog-
raphy, AOPP are retrieved in two distinct peaks at 600
and below 80 kDa in uremic plasma, while no such peaks
are found in control plasma.
Determination of NGAL
This biomarker was determined in specimens of plasma
that were stored at −80 °C until analysis. Blood speci-
mens were collected aseptically into EDTA-containing
tubes, centrifuged at 3000 rpm and serum separated and
stored at −80 °C until testing. Plasma level of NGAL was
measured with a commercially available ELISA kit pur-
chased from Bio Porto Diagnostics (Gentofte, Denmark).
Haptoglobin phenotype
Haptoglobin phenotype was determined as described by
Hochberg et al. [43]. Briefly, serum (10 μL) was mixed
with 2 μL of a 10 % hemoglobin solution, and the samples
were incubated for 5 min at room temperature to permit
the haptoglobin-hemoglobin complexes to form. The
haptoglobin-hemoglobin complex was resolved by poly-
acrylamide electrophoresis. The haptoglobin-hemoglobin
complexes were visualized by soaking the gel in freshly
prepared staining solution. The bands corresponding to
the haptoglobin-hemoglobin complex were readily visible
within 15 min. All gels were documented with photo-
graphs. Phenotypes Hp 1–1, Hp 2–2, and Hp 2–1 were
distinguished by a characteristic pattern of bands repre-
senting the haptoglobin-hemoglobin complexes.
Statistical analysis
Data are expressed as means ± SEM. Microsoft Excel
software was used to analyze data, create standard
curves and draw figures. Statistical significance was
assessed by one-way analysis of variance (ANOVA) for
repeated measures. Tukey’s multiple comparisons test
was used for data point comparisons in each group. P ≤
0.05 was considered statistically significant.
Results and discussion
The average age of the studied 26 patients was 63.8 ±
2.84 years (Table 1). Thirteen of them were males and
the rest females. Administration of IVIR for 4 weeks
did not increase hemoglobin levels (10.23 ± 0.28 vs.
10.31 ± 0.28 g % p =NS) (Table 2), yet worsened the oxi-
dative burden as was evident by elevated plasma AOPP
from basal value of 229.1 ± 27.32 to 318.1 ± 39.63 μM
(p < 0.05), and 367.8 ± 41.8 (p < 0.05) after 1 and 4 weeks,
respectively (Fig. 2). Plasma NGAL levels were not signifi-
cantly affected by IVIR (265.4 ± 48.55 vs. 265.1 ± 44.7 and
205.7 ± 39.41 ng/ml, after 1 and 4 weeks, respectively)
(Fig. 3). Simultaneous administration of carnitine with
IVIR resulted in a mild hemoglobin increase (11.18 ±
0.26 g %, p =NS) (Table 2). Interestingly, carnitine therapy
abolished the IVIR-induced oxidative stress as evident by
preventing the elevations in AOPP (228.7 ± 31.85 vs.
237.4 ± 31.85 and 271.8 ± 23.8 μM after 1 and 4 weeks, re-
spectively, p = NS) (Fig. 2). Furthermore, carnitine therapy
decreased NGAL levels from 281.8 ± 49.41 to 201.3 ±
36.63 (p < 0.05), and 239 ± 48.55 ng/ml (p < 0.05) after 1
and 4 weeks, respectively (Fig. 3). No changes in CRP,
Serum Cr, BUN, albumin or WBC were observed fol-
lowing IVIR alone or combined with carnitine (Table 2).
These findings indicate that IVIR in CKD patients pro-
vokes oxidative stress, as evident by elevation of circu-
lating AOPP. Our finding, that co-administration of
carnitine with IVIR attenuates the adverse conse-
quences of IVIR, suggests a role for carnitine therapy
also in earlier-stage CKD patients.
Haptoglobin phenotype
This protocol was designed in order to examine whether
Hp phenotype affects iron-induced oxidative stress in
CKD patients. Figure 4 depicts the distribution of Hp
gene polymorphism among the studied CKD patients.
Eight percent of the CKD patients were Hp 1–1, 19 %
Table 2 Effect of Carnitine therapy on biochemical and hematological characteristics of patients with CKD treated with intravenous
administration of iron
Parameter Pre IVIR-W1 Post IVIR-W1 Post IVIR-W4 Pre IVIR + CAR-W5 Post IVIR + CAR-W5 Post IVIR + CAR-W8
Creatinine (mg %) 2.5 ± 0.31 2.48 ± 0.36 2.38 ± 0.32 2.43 ± 0.31 2.27 ± 0.35 2.59 ± 0.44
Albumin (g %) 4.05 ± 0.08 3.88 ± 0.09 3.83 ± 0.07 4.08 ± 0.07 3.92 ± 0.06 3.98 ± 0.1
BUN (mg %) 42.4 ± 5.4 42.5 ± 6.3 37.3 ± 4.5 43.6 ± 5.7 38.6 ± 5.6 45.3 ± 8.1
CRP 0.74 ± 0.19 0.61 ± 0.13 0.54 ± 0.11 0.66 ± 0.11 0.53 ± 0.09 0.94 ± 0.32
WBC 6.67 ± 0.49 6.65 ± 0.49 5.92 ± 0.43 6.65 ± 0.55 6.25 ± 0.54 6.64 ± 0.58
NEU % 66.7 ± 1.65 67.3 ± 1.66 66.5 ± 1.67 68.9 ± 1.46 66.3 ± 1.85 64.95 ± 1.86
LYM % 22.3 ± 1.3 22.3 ± 1.5 23.2 ± 1.56 20.4 ± 1.26 23.3 ± 1.51 23.65 ± 1.6
Hb (g %) 10.3 ± 0.25 10.0 ± 0.33 10.5 ± 0.21 10.8 ± 0.19 10.4 ± 0.17 11.02 ± 0.22
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Hp 2–1, and 73 % Hp 2–2. The alterations in plasma
AOPP and NGAL in response to IVIR in the absence or
presence of carnitine therapy in these patients according
to their Hp phenotype are depicted in Fig. 5. As can be
noticed, the increase in AOPP after 4 weeks from IVIR
administration was more prominent in Hp 2–2 patients
(Fig. 5a). Carnitine therapy reduced plasma levels of
NGAL in Hp 2–2 patients administered with IVIR more
profoundly than that observed in Hp2-1 subjects (Fig. 5b).
The present study provides new insights into the
mechanisms underlying the oxidative stress response to
intravenous administration of iron (IVIR) to predialytic
CKD patients. We showed that IVIR to these patients
provoked oxidative stress as was evident by elevated
levels of AOPP. Carnitine therapy significantly reduced
the oxidative stress response to IVIR as expressed by
lower levels of AOPP. Although, IVIR did not increase
circulatory levels of NGAL, administration of carnitine
decreased plasma levels of NGAL below basal concen-
trations. Noteworthy, overwhelming majority of CKD
patients are of Hp 2–2 phenotype. The latter were more
sensitive to the oxidative stress response to IVIR than
Fig. 2 Effects of Carnitine therapy on AOPP levels in patients with CKD treated with intravenous administration of iron. AOPP levels were
determined in blood samples drawn 1 and 8 weeks prior and post iron administration (Sodium ferric gluconate, 125 mg/100 ml) During weeks
5–8, these patients received carnitine (20 mg/kg, IV) prior to IVIR
Fig. 3 Effects of Carnitine therapy on plasma NGAL levels in patients with CKD treated with intravenous administration of iron. NGAL levels were
determined in blood samples drawn 1 and 8 weeks prior and post iron administration (Sodium ferric gluconate, 125 mg/100 ml) During weeks
5–8, these patients received carnitine (20 mg/kg, IV) prior to IVIR
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others, suggesting that Hp gene polymorphism plays a
role in the pathogenesis of IVIR-induced oxidative stress.
Unfortunately, IVIR administration for 8 weeks did not
increase Hb levels in CKD patients. However, simultan-
eous administration of Carnitine with IVIR resulted in a
mild elevation of hemoglobin concentrations. No changes
in CRP, Serum Cr, BUN, albumin or WBC were observed
following IVIR alone or combined with Carnitine.
Oxidative stress is a constant feature of patients with
CKD and a major risk factor for cardiovascular, neuro-
logical and other clinical complications characterizing
this disease [4–6]. Intravenous administration of iron in
conjunction with EPO is frequently utilized in order to
correct the anemia associated with CKD [7, 9, 10]. Al-
though iron administration composes an essential com-
ponent of CKD therapy, concerns have emerged about
its promotion of oxidative stress and related adverse im-
pact. The deleterious pro oxidative effects were exten-
sively studied mainly in dialytic patients [10, 16] and to
a lesser extent in pre dialytic subjects [11]. Whether pa-
tients with CKD not on dialysis have a similar increase
in oxidative stress and, above all, renal injury upon ex-
posure to intravenous iron is unknown. This issue is of
critical importance since oxidative stress and renal injury
may accelerate renal deterioration and increase the risk
of cardiovascular disease [4–6, 44]. Thus, the current
study addresses this matter and extends our knowledge
in that respect. Our findings clearly show that IVIR ad-
ministration for few weeks induced oxidative stress also
in pre dialytic CKD patients. This was evident by a sig-
nificant elevation of AOPP, a marker of plasma proteins
oxidation. These findings are in agreement with those of
Anraku et al. [44] who demonstrated elevated levels of
AOPP following IVIR for 4 weeks to dialytic patients.
Drüeke et al. [45] demonstrated that advanced oxidation
protein products (AOPPs) correlated with iron exposure
and carotids artery intima thickness in dialysis patients.
In hemodialysis patients, oxidative stress as a result of
intravenous iron therapy caused serum albumin oxida-
tion [46]. Similar to our findings, Agarwal et al. [11]
demonstrated that 100 mg iron sucrose over 5 min to
patients with CKD at stages 3 and 4 increased plasma
concentration and urinary excretion rate of MDA, a bio-
marker of lipid peroxidation, within 15 to 30 min of iron
sucrose administration. In contrast to the stimulatory ef-
fect of IVIR on AOPP, our findings show that NGAL did
not increase following iron administration. NGAL is up-
regulated and overexpressed following AKI, and its
plasma and urinary levels increased early after renal is-
chemia in mouse and rat models [34], and following
renal ischemic insult in human undergoing pulmonary
bypass surgery [32]. The lack of stimulatory effects of
IVIR on plasma NGAL in our patients indicates that
iron administration did not cause serious AKI [47]. It
should be emphasized that plasma NGAL also increases
during inflammatory diseases and infections [32], sug-
gesting that the decline in plasma NGAL when carnitine
was added could be attributed to the anti-inflammatory
effect of carnitine.
So far there is no effective pharmacological therapy for
oxidative stress-induced by iron administration. Neither
vitamin C nor vitamin E supplementation was found to
ameliorate oxidative stress and inflammation in ESRD
patients [48]. Likewise, NAC reduced acute generation
Fig. 4 Distribution of haptoglobin phenotype among the studied CKD patients
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of systemic oxidative stress but failed to abrogate pro-
teinuria or enzymuria induced by 100 mg iron sucrose
to CKD patients [11]. In this context, animal and human
data demonstrate beneficial effects of carnitine in experi-
mental models and clinical settings of oxidative stress in-
cluding hemodialysis [49].
Experimental studies shows beneficial effects of L-
propionylcarnitine, a propionyl ester of L-carnitine, in pre-
venting cyclosporine-induced acute nephrotoxicity, redu-
cing lipid peroxidation and significantly lowering blood
pressure. L-propionyl carnitine prevented the decline in
creatinine clearance (GFR) in cyclosporine chronically
treated animals [50]. Clinical studies revealed that ESRD
patients treated with carnitine displayed improved phys-
ical performance and treatment-related chronic fatigue,
cardiovascular disease, cancer, diabetes, and other chronic
syndromes, related to impaired carnitine production in
kidney disease [49]. In the last decade there are increasing
reports describing the beneficial use of carnitine for a bet-
ter energy metabolism (mitochondrial metabolism). In this
context Carnitine increases albumin and protein levels, re-
stores antioxidant defenses, and improves nutritional sta-
tus, cardiac, vascular smooth muscle, and muscular
function [51]. The postulated beneficial effect of carnitine
treatment is due to directing lipids towards oxidation and
ATP production. Another possible protective effect of car-
nitine on CKD is its ability to suppress the development
of oxidative stress and free radical generation [52]. In line
with this notion, our results clearly indicate anti-oxidative
properties of carnitine as was evident by reducing AOPP
and NGAL levels in CKD patients treated with IVIR.
Finally, our study is the first to our knowledge to investi-
gate the impact of Hp gene polymorphism on the oxida-
tive response to IVIR to CKD patients. Interestingly, most
Fig. 5 Effect of Haptoglobin phenotype on a) AOPP and b) NGAL levels in patients with CKD treated with intravenous administration of iron.
AOPP and NGAL levels were determined in blood samples drawn 1 and 8 weeks prior and post iron administration (Sodium ferric gluconate,
125 mg/100 ml). During weeks 5–8, these patients received Carnitine (20 mg/kg, IV) prior to IVIR administration
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of the studied patients were Hp 2–2 (73 %) whereas only
8 % were Hp 1–1. Similarly, the frequency of Hp2-2 geno-
type allele was significantly higher in the CKD Taiwanese
patients than in controls [53]. After adjustment for covari-
ates, the Hp2-2 genotype (vs. Hp1-1; OR 3.841) remained
significantly associated with the development of CKD, to-
gether with diabetes (OR 3.131), hypertension (OR 1.748)
and dyslipidemia (OR 1.646). Taking into account that Hp
plays a role in renal protection, these findings suggest
Hp2-2 genotype is an independent risk factor for CKD.
Our data support this concept and show that CKD pa-
tients of Hp2-2 allele are more prone to develop oxidative
stress in response to IVIR than other Hp alleles. Add-
itional larger and longer clinical trials are requested to ver-
ify this concept.
Conclusions
This study demonstrates that intravenous administration
of iron to CKD patients provokes oxidative stress as
expressed by elevated AOPP levels. Administration of
Carnitine to CKD patients reduces the oxidative burden
induced by IVIR. The anti-oxidative effects of Carnitine,
suggests a role for Carnitine therapy also in earlier-stage
CKD patients. Since Hp 2–2 is a significant risk factor
for IVIR-induced oxidative stress in CKD patients, the
latter may benefit from carnitine therapy more than
other Hp genotypes.
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